Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Short DAPT Patients

Contact Customer Service

Xience™ Stent: Protecting Patients with Short DAPT Needs

Dual antiplatelet therapy (DAPT) duration often depends on the patient—and it may depend on the stent as well.

XIENCE™ Stent Has the Largest Body of DAPT Patient Evidence3

More than 24,000 patients have been analyzed in short DAPT trials with XIENCE Stent

XIENCE™ Stent is the only DES with results showing 1-month DAPT data and 3-month DAPT data for both aspirin and P2Y12 inhibitor monotherapy—including data on patients at high bleeding risk (HBR).4

Among all 3 categories outlined above—aspirin monotherapy, P2Y12 inhibitor monotherapy and HBR patients—XIENCE™ Stent data revealed very low rates of stent thrombosis (ST) at 12 months.5

≤ 0.3% Definite ST At 1 Year5

XIENCE™ Stent differs from competitors: its short DAPT studies include HBR patients and different monotherapies
Comparison of Short DAPT Studies by Stent Type

XIENCE 28 and XIENCE 90 Study Results6

XIENCE™ Stent Short DAPT: Ischemic Events

Among HBR patients, XIENCE™ Stent with 1-month or 3-month DAPT reduced severe bleeding with no increase in ischemic events, including myocardial infarction (MI) and all death.6

XIENCE 28: 1-month DAPT in HBR Patients
XIENCE 28: All Death or MI

Between 1 and 6 months
With XIENCE™ Stent, there is no increase in all death or MI using 1-month DAPT or 3-month DAPT vs 6-month DAPT or 12-month DAPT, respectively

XIENCE 90: 3-month DAPT in HBR Patients
XIENCE 90: All Death or MI

Between 3 and 12 months
With XIENCE™ Stent, there is no increase in all death or MI using 1-month DAPT or 3-month DAPT vs 6-month DAPT or 12-month DAPT, respectively

XIENCE™ Stent Short DAPT: Reduced Severe Bleeding

In the same HBR population, XIENCE™ Stent with 1-month or 3-month DAPT reduced severe bleeding with no increase in ischemic events.6,*

XIENCE 28: BARC 3-5 Bleeding

Between 1 and 6 months
With DAPT halted at either 1 month and 3 months, XIENCE™ Stent showed less severe bleeding, at 6 months and 12 months, vs earlier XIENCE™ Stent data

XIENCE 90: BARC 3-5 Bleeding

Between 3 and 12 months
With DAPT halted at either 1 month and 3 months, XIENCE™ Stent showed less severe bleeding, at 6 months and 12 months, vs earlier XIENCE™ Stent data

*Propensity score stratified analysis for BARC 3-5 bleeding was not pre-specified. BARC 2-5 was a powered secondary endpoint. In both studies, for BARC 2-5, XIENCE™ Stent showed numerically lower bleeding rate for 1-month or 3-month DAPT versus 6-month DAPT or 12-month DAPT, respectively.
 

XIENCE™ Stent Short DAPT: Continued Low Stent Thrombosis

XIENCE™ Stent is recognized for its low ST rate, and it is significantly more anti-thrombotic than other DES.7 This is evident even with short DAPT data. XIENCE™ Stent with 1-month DAPT showed no increase in ST vs 6-month DAPT—with an ST rate of 0.3%. Similarly, the 3-month DAPT showed an ST rate of 0.2%.6

XIENCE 28: Stent Thrombosis

Between 1 and 6 months
ARC : Definite/Probable ST
XIENCE™ Stent with short DAPT shows consistently low rates of stent thrombosis: 1-month and 6-month DAPT are both 0.3% ST, 3-month and 12-month DAPT are both 0.2% ST

XIENCE 90: Stent Thrombosis

Between 3 and 12 months
ARC : Definite/Probable ST
XIENCE™ Stent with short DAPT shows consistently low rates of stent thrombosis: 1-month and 6-month DAPT are both 0.3% ST, 3-month and 12-month DAPT are both 0.2% ST

XIENCE™ Stent Is Anti-Thrombotic: Suited for Short DAPT

The XIENCE™ Stent is also recognized as being significantly more anti-thrombotic than other DES on the market. As shown in the study findings, XIENCE™ Stent reveals significantly less (p < 0.01) platelet adhesion—shown in red in the confocal microscopy images—than other DES, and platelet adhesion is an important factor in stent thrombosis.8 These findings suggest that this stent choice “may be ideally suited for very short-term DAPT.”8

XIENCE™ Stent is thromboresistant, showing significantly less (p < 0.01) platelet adhesion than Synergy,‡ Orsiro,‡ Ultimaster,‡ Onyx,‡ and BioFreedom‡ DES.

STOPDAPT Studies: 1-Month DAPT and 3-Month DAPT in All-Comers Population9,10

STOPDAPT9 and STOPDAPT 210 were prospective trials of the XIENCE™ Stent that studied DAPT cessation at 3 months and 1 month, respectively

STOPDAPT 2 Trial: 1-Month DAPT Superior to 12-Month DAPT10

The STOPDAPT 2 trial revealed that 1-month DAPT demonstrated superior safety over 12-month DAPT for the primary endpoint of net adverse cardiovascular events (NACE). NACE included cardiovascular death, myocardial infarction (MI), definite ST, stroke, or thrombolysis in MI (TIMI) major/minor bleeding. All of the 3,009 patients in this randomized, controlled trial were treated with XIENCE™ Stent.10


Significantly Lower NACE* with 1-Month DAPT

With XIENCE™ Stent, 1-month DAPT is superior to 12-month DAPT for net adverse cardiovascular events


Significantly Lower Bleeding Events* with 1‑Month DAPT

With XIENCE™ Stent, there is significantly lower risk of bleeding events with 1-month DAPT vs 12-month DAPT


Comparable Ischemic Event Rates* with 1‑Month DAPT

With XIENCE™ Stent, 1-month DAPT and 12-month DAPT show comparable ischemic event rates of 2.0% to 2.5%
Learn more about STOPDAPT 2

STOPDAPT 2 Trial Design and Randomization

Short 1-Month DAPT

  • 0 to 1-month: Aspirin + P2Y12
  • After 1-month: Clopidogrel monotherapy
Exclusion criteria in STOPDAPT 2 included patients on oral anticoagulants, with a history of intracranial bleeding, and with major in-hospital complications such as MI, stroke or major bleeding

12-Month DAPT

  • 0 to 1-month: Aspirin + P2Y12
  • 1 to 12-month: Aspirin + Clopidogrel
  • 12 to 60-month: Aspirin monotherapy
Exclusion criteria in STOPDAPT 2 included patients on oral anticoagulants, with a history of intracranial bleeding, and with major in-hospital complications such as MI, stroke or major bleeding
  1. Successful PCI using CoCr everolimus-eluting stent: XIENCE™
  2. Eligible for DAPT (aspirin/P2Y12 receptor blocker) for 1 year

 

Key inclusion criteria
  1. Patients who need oral anticoagulants
  2. History of intracranial bleeding
  3. Major in-hospital complications (MI/stroke/major bleeding)

 

Key exclusion criteria


STOPDAPT Study: XIENCE™ Stent with 3-Month DAPT Is Feasible9

STOPDAPT9 was the first prospective trial to study DAPT cessation at 3 months after implantation. Among other 1-year outcomes, the XIENCE™ Stent rate of stent thrombosis was 0.0%.

XIENCE™ Stent 1-year data, when using 3-month DAPT, shows 0.0% definite or probable stent thrombosis
STOPDAPT Study Demonstrates Feasibility of XIENCE™ Stent with 3-Month DAPT9

“Stopping DAPT at 3 months in selected patients after [XIENCE™ Stent] implantation was at least as safe as the prolonged DAPT regimen adopted in the historical control group.”

— Masahiro Natsuaki, MD, STOPDAPT Trial9

Expert Panel Discussion on STOPDAPT 2 and Short DAPT Strategies for PCI Patients

“It was noteworthy that no definite or probable stent thrombosis occurred in [XIENCE™ Stent] patients enrolled in STOPDAPT.”

— Masahiro Natsuaki, MD, STOPDAPT Trial9

  • Manuals & Technical Resources
    Manuals & Technical Resources
    Search
  • Cardiovascular Products
    Cardiovascular Products
    Order
  • Customer Service
    Customer Service
    Contact Us

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Valgimigli M, et al. TCT Connect 2020 – XIENCE 28. Mehran R, et al. TCT Connect 2020 – XIENCE 90.
  3. Généreux P, et al. Circ Cardiovasc Interv. 2015;8(5):e00136. Natsuaki M, et al. Cardiovasc Interv Ther. 2016;31:196–209. Watanabe H, et al. JAMA. 2019;321(24):2414-2427. Hahn J, et al. ACC 2019 – SMART CHOICE. Valgimigli M, et al. Circulation. 2012;125:2015-2026. Gilard M, et al. J Am Coll Cardiol. 2015;65:777-786. Hong SJ, et al. JACC Cardiovasc Interv. 2016;9:1438–1446. Gwon HC, et al. ACC 2011 – EXCELLENT. Mehran R, et al. TCT Connect 2020 – XIENCE 28/90.
  4. Mehran R, et al. TCT Connect 2020 – XIENCE 28/90. Watanabe H, et al. JAMA. 2019;321(24):2414-2427. Hahn J, et al. ACC 2019 – SMART CHOICE. Varenne O, et al. Lancet. 2018.391:41-50 – SENIOR. Kirtane A, et al. TCT 2019 – EVOLVE Short DAPT. Kedhi E, et al. PCT eCourse 2020 – OnyxOne; Postma W, et al. Cather Cardiovasc Interv. 2020;95:706-710 – DAPT-STEMI.
  5. Mehran R, et al. TCT Connect – 2020 XIENCE 28/90. Watanabe H, et al. JAMA. 2019;321(24):2414-2427. Natsuaki M, et al. Cardiovasc Interv Ther. 2016;31:196–209.
  6. Mehran R, et al. TCT Connect 2020 – XIENCE 28/90.
  7. Valgimigli M, et al. TCT Connect 2020 – XIENCE 28. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74(Suppl B):B290 – TCT-291.
  8. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74(Suppl B):B290 – TCT-291.
  9. Natsuaki M, et al. Cardiovasc Interv Ther. 2016;31:196–209.
  10. Watanabe H, et al. JAMA. 2019;321(24):2414-2427.

MAT-2101787 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO